Shearman & Sterling Advises on Golden Meditech’s $830 Million Sale of Stake in China Cord Blood
Shearman & Sterling is advising Hong Kong-listed Golden Meditech, a leading integrated healthcare company engaged in the development, manufacture, sales and distribution of blood-related medical devices and hospital management in China, on the sale of its stake in China Cord Blood for US$830 million. The transaction is expected to be completed by the first quarter of 2017.
Listed on the New York Stock Exchange, China Cord Blood is a leading provider of cord blood processing and storage services and is also the largest cord blood banking operator in China.
The Shearman & Sterling team included partner Paul Strecker
(London/Hong Kong-Mergers & Acquisitions); and associates Richard Ou (Hong Kong-Mergers & Acquisitions), Shan Wu and Weina Guan (both Beijing-Mergers & Acquisitions).